Inspra (Eplerenone)

Eplerenone selectively blocks mineralocorticoid (aldosterone) receptors in the kidney. This inhibition reduces sodium reabsorption and promotes potassium retention, leading to increased urine output of sodium and water, lower blood volume, and reduced blood pressure. The same receptor blockade also limits aldosterone‑driven cardiac remodeling, which benefits patients with heart failure.

The exact dose of eplerenone is determined by the prescribing clinician based on the individual’s medical condition, kidney function, and potassium levels. Typical starting doses may be adjusted over time, but patients should follow the specific instructions provided by their healthcare professional and not alter the regimen without consultation.

Safety data for eplerenone in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative therapies with their physician, as other antihypertensive options may be preferred.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

The primary alternative to eplerenone is spironolactone, another mineralocorticoid receptor antagonist. Eplerenone is more selective for the aldosterone receptor, which generally results in fewer hormonal side effects such as gynecomastia. However, both drugs share similar efficacy in lowering blood pressure and improving heart‑failure outcomes, and dosing must be individualized.

Inspra should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure the container is tightly closed to maintain product stability.

Inspra is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed, and they should adhere to the prescribed schedule to maintain consistent blood levels.

The most critical risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute kidney injury, which may manifest as reduced urine output or elevated creatinine. Additionally, rare but serious reactions such as angioedema or severe allergic responses require immediate medical attention. Regular laboratory monitoring helps detect these issues early.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone or any component of the formulation, those with existing hyperkalemia (serum potassium >5.0 mmol/L), and individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²). It should also be avoided in patients taking other potassium‑sparing agents unless closely monitored by a physician.